VSM MedTech upgrades to TSX (Toronto Stock Exchange):
This article was originally published in Clinica
Canadian company VSM MedTech's shares have begun trading on the Canada's senior stock exchange, the Toronto Stock Exchange (TSX), and have been delisted from the TSX Venture Exchange. The Vancouver-based company's noninvasive technologies include imaging systems for mapping adult and foetal brain function and monitoring devices for the accurate measurement of blood pressure. "We anticipate that listing on the TSX will provide the company with increased visibility within the investment community as the company moves forward in the execution of its growth strategy," said Barry Allen, president and CEO.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.